Phase I Study of Bryostatin 1 (NSC 339555) and Fludarabine in Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma.

Trial Profile

Phase I Study of Bryostatin 1 (NSC 339555) and Fludarabine in Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2010

At a glance

  • Drugs Bryostatin-1 (Primary) ; Fludarabine (Primary)
  • Indications Chronic lymphocytic leukaemia; Hairy cell leukaemia; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Mar 2010 Actual patient number (54) added as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Actual end date (August 2006) added as reported by ClinicalTrials.gov.
    • 22 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top